Prima BioMed Ltd (NASDAQ:PBMD)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a research note issued on Thursday. They currently have a $7.00 price objective on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 316.67% from the company’s previous close.

Separately, Zacks Investment Research upgraded Prima BioMed from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Wednesday, May 3rd.

Shares of Prima BioMed (PBMD) traded up 1.20% on Thursday, hitting $1.68. The stock had a trading volume of 206,797 shares. The firm’s 50-day moving average is $1.64 and its 200-day moving average is $2.20. Prima BioMed has a one year low of $1.40 and a one year high of $3.26. The company’s market cap is $35.54 million.

ILLEGAL ACTIVITY NOTICE: “Maxim Group Reaffirms Buy Rating for Prima BioMed Ltd (PBMD)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at

About Prima BioMed

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Receive News & Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related companies with's FREE daily email newsletter.